BioNxt Solutions Inc. (CSE:BNXT)

Market Cap	64.63M
Revenue (ttm)	42.01K
Net Income (ttm)	-6.48M
Shares Out	115.41M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	81,200
Average Volume	106,208
Open	0.5600
Previous Close	0.5600
Day's Range	0.5300 - 0.5600
52-Week Range	0.1700 - 0.6900
Beta	0.57
RSI	55.06
Earnings Date	Apr 22, 2025

About BioNxt Solutions

BioNxt Solutions Inc. engages in R&D and manufacturing of thin-film (sublingual) and skin patch (transdermal) drug delivery for neurological and autoimmune diseases, enhancing patient compliance and bioavailability. It offers diagnostic screening tests, and new active pharmaceutical production and evaluation, including precision transdermal and oral dissolvable drug formulations; oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The company was f...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2017
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: BNXT

Financial Performance

In 2023, BioNxt Solutions's revenue was 372,247, an increase of 25.15% compared to the previous year's 297,442. Losses were -7.72 million, -37.60% less than in 2022.